It involved 1,795 adults, ages 50 to 90, with mild cognitive impairment due to early Alzheimer’s disease or mild Alzheimer’s disease-related dementia.
Such a score is consistent with early Alzheimer’s disease, with a higher number associated with more cognitive impairment.
By 18 months, the CDR-SB score went up 1.21 points in the lecanemab group, compared with 1.66 in the placebo group.
Overall, there were serious adverse events in 14% of the lecanemab group and 11.3% of the placebo group.
The researchers also wrote that about 0.7% of participants in the lecanemab group and 0.8% of those in the placebo group died, corresponding to six deaths documented in the lecanemab group and seven in the placebo group.